Experimental hepatitis b drug shows promise in early trial
NCT ID NCT02065336
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new drug called ARC-520, given with the standard medicine entecavir, could lower hepatitis B virus levels in people with chronic hepatitis B. About 58 adults with different stages of infection received either ARC-520 or a placebo. The study was stopped early, but it aimed to see how much and how long the virus surface antigen stayed reduced.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site 1
Pokfulam, Hong Kong
-
Research Site 2
Shatin, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Can a Two-Drug combo finally beat chronic hepatitis b?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Experimental drug aims for functional cure in hepatitis b
- 10-Year hepatitis study aims to unlock secrets of liver disease
- New shot aims to tame hepatitis b without daily pills